Dr Baselga presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III trial of taselisib, a PI3K targeted therapy, used in combination with hormone therapy fulvestrant.

He describes how the combination halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%.

For more on these results, read our news coverage here.

Slides from this presentation are available here.